» Articles » PMID: 8989430

CD8+ T Cells from HIV Type 1-seronegative Individuals Suppress Virus Replication in Acutely Infected Cells

Overview
Publisher Mary Ann Liebert
Date 1997 Jan 1
PMID 8989430
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

CD8+ lymphocytes (CD8 cells) have been shown to inhibit replication of the human immunodeficiency virus (HIV) in vitro when cocultured with HIV-infected CD4+ lymphocytes (CD4 cells). This suppressive effect on HIV replication in experimentally infected CD4 cells has so far been demonstrated only for CD8 cells from HIV-seropositive individuals. In the present study we have investigated if CD8 cells from HIV-negative individuals can also suppress HIV replication in experimentally infected CD4 cells. Positively selected CD4 cells were infected with phenotypically different primary isolates of HIV type 1 and 2 (HIV-1 and HIV-2). Graded numbers of CD8 cells were added to the infected cultures. The T cells were activated by antibodies directed against the CD3 molecule or the T cell receptor. Culture supernatants were harvested for HIV p24 quantitation and the CD8 suppression of HIV replication was calculated by comparing p24 levels from parallel cultures in the presence or absence of CD8 cells from different donors. We show that CD8 cells from unexposed HIV-seronegative blood donors are able to control HIV-1 and HIV-2 replication in experimentally infected autologous CD4 cells. The antiviral activity of CD8 cells from and HIV-naive individual was reproducible over time and the suppressive effect was comparable to that seen with CD8 cells from HIV-positive individuals. The infected cells were not eliminated from the cultures. The suppressive effect of CD8 cells varied depending on the dose and biological phenotype of the virus used for infection. Thus, exposure to HIV in vivo is not a prerequisite for CD8 cells to exert a suppressive effect on HIV replication in acutely infected cells.

Citing Articles

The CD8 T Cell Noncytotoxic Antiviral Responses.

Morvan M, Teque F, Locher C, Levy J Microbiol Mol Biol Rev. 2021; 85(2).

PMID: 33980586 PMC: 8139528. DOI: 10.1128/MMBR.00155-20.


Analysis of the CD8 T cell anti-HIV activity in heterologous cell co-cultures reveals the benefit of multiple HLA class I matches.

Killian M, Teque F, Sudhagoni R Immunogenetics. 2017; 70(2):99-113.

PMID: 28735348 DOI: 10.1007/s00251-017-1021-7.


Anti-HIV designer T cells progressively eradicate a latently infected cell line by sequentially inducing HIV reactivation then killing the newly gp120-positive cells.

Sahu G, Sango K, Selliah N, Ma Q, Skowron G, Junghans R Virology. 2013; 446(1-2):268-75.

PMID: 24074590 PMC: 3791854. DOI: 10.1016/j.virol.2013.08.002.


HIV and the chemokine system: 10 years later.

Lusso P EMBO J. 2006; 25(3):447-56.

PMID: 16437164 PMC: 1383531. DOI: 10.1038/sj.emboj.7600947.


Changes in soluble factor-mediated CD8+ cell-derived antiviral activity in cynomolgus macaques infected with simian immunodeficiency virus SIVmac251: relationship to biological markers of progression.

Dioszeghy V, Benlhassan-Chahour K, Delache B, Dereuddre-Bosquet N, Aubenque C, Gras G J Virol. 2005; 80(1):236-45.

PMID: 16352548 PMC: 1317544. DOI: 10.1128/JVI.80.1.236-245.2006.